| Literature DB >> 34307431 |
Anna Song1, Rashmi Deshmukh2, Haotian Lin3, Marcus Ang4, Jodhbir S Mehta4, James Chodosh5, Dalia G Said6,7, Harminder S Dua6,7, Darren S J Ting6,7.
Abstract
Post-keratoplasty infectious keratitis (PKIK) represents a unique clinical entity that often poses significant diagnostic and therapeutic challenges. It carries a high risk of serious complications such as graft rejection and failure, and less commonly endophthalmitis. Topical corticosteroids are often required to reduce the risk of graft rejection but their use in PKIK may act as a double-edged sword, particularly in fungal infection. The increased uptake in lamellar keratoplasty in the recent years has also led to complications such as graft-host interface infectious keratitis (IIK), which is particularly difficult to manage. The reported incidence of PKIK differs considerably across different countries, with a higher incidence observed in developing countries (9.2-11.9%) than developed countries (0.02-7.9%). Common risk factors for PKIK include the use of topical corticosteroids, suture-related problems, ocular surface diseases and previous corneal infection. PKIK after penetrating keratoplasty or (deep) anterior lamellar keratoplasty is most commonly caused by ocular surface commensals, particularly Gramme-positive bacteria, whereas PKIK after endothelial keratoplasty is usually caused by Candida spp. Empirical broad-spectrum antimicrobial treatment is the mainstay of treatment for both PKIK, though surgical interventions are required in medically refractory cases (during the acute phase) and those affected by visually significant scarring (during the late phase). In this paper, we aim to provide a comprehensive overview on PKIK, encompassing the epidemiology, risk factors, causes, management and outcomes, and to propose a treatment algorithm for systematically managing this challenging condition.Entities:
Keywords: corneal graft; corneal infection; corneal transplant; corneal ulcer; eye bank; interface infectious keratitis; keratoplasty; steroid
Year: 2021 PMID: 34307431 PMCID: PMC8292647 DOI: 10.3389/fmed.2021.707242
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Figure 1Examples of post-keratoplasty infectious keratitis (PKIK). (A) A case of PKIK caused by Streptococcus pneumonia in an eye after Descemet membrane endothelial keratoplasty, while on topical corticosteroids. (B) A case of suture-related PKIK caused by Staphylococcus aureus in an eye after penetrating keratoplasty. (C,D) A case of PKIK caused by Pseudomonas aeruginosa in an eye with failed Descemet stripping automated endothelial keratoplasty with bullous keratopathy, while on topical steroids. (C) demonstrates the presence of decompensated corneal graft prior to the infection. (E,F) A case of PKIK caused by Moraxella catarrhalis in an eye with failed penetrating keratoplasty with bullous keratopathy, while on topical steroids.
Figure 2A case of interface infectious keratitis (IIK) following Descemet stripping automated endothelial keratoplasty (DSAEK). (A,B) Slit-lamp photography demonstrating an inflamed right eye with diffused stromal haze in a crisscross pattern at the graft-host interface (blue arrows), consistent with a diagnosis of IIK. The edge of the DSAEK graft is visible (yellow arrow). The hyper-reflective changes at the graft-host interface (red arrows) are clearly delineated on anterior segment optical coherence tomography (AS-OCT) highlighting the value of AS-OCT in facilitating the assessment of infectious, keratitis. (C,D) Slit-lamp photography demonstrating a complete resolution of the IIK following intensive topical anti-fungal treatment, evidenced by the disappearance of the stromal haze on slit-lamp photograph and the hyper-reflective changes at the graft-host interface on AS-OCT. (A) is reproduced from Ting et al. (22) with permission.
Figure 3A proposed systematic treatment algorithm of post-keratoplasty infectious keratitis (PKIK). *The proposed surgical approach is related to the management of graft-host interface infectious keratitis. **Some may also consider removal of the donor lenticule + intracameral antimicrobial treatment.
Figure 4A case of right recurrent interface infectious keratitis (IIK) after deep anterior lamellar keratoplasty (using manual dissection technique) for keratoconus. (A,B) Slit-lamp photography in Aug 2018 demonstrating a suture-related infection, with a mid-stromal infiltrate and a small overlying epithelial defect along the suture track at 7 o'clock (red arrows), with surrounding stromal oedema/folds. The infected broken suture was removed, and the infection was successfully resolved with topical antibiotic treatment. (C,D) A year later, slit-lamp photography showing a recurrent mid-to-deep stromal infiltrate (involving the graft-host interface) at the same site with inferior corneal graft vascularization, suggesting an atypical presentation of IIK. The recurrence was likely due to a “reactivation” of the previously treated infective nidus at the graft-host interface. (E) Improvement of the superficial infection was observed after two weeks of intensive antibiotic treatment. The residual IIK (yellow arrow) was resolved after a further 3 weeks of topical antibiotic treatment. (F) Further recurrence of infection was again observed in October 2020. Note the gradual migration of the infection towards the visual axis along the graft-host interface, compared to the previous years. (G) The patient was treated for a mixed bacterial/fungal infection with intensive topical antibiotic and antifungal treatment, but only a partial response was observed. A course of repeated intrastromal injections of voriconazole 0.1% (0.1 ml) was subsequently given every weekly for 4 weeks. (H) Complete resolution of infection was achieved, with a residual scar.
| Dohse et al. ( | 2020 | 2007–2018 | US | 2,098 | PK and EK | 86 | 64.7 ± 21.7 | 59.3 | 4.1 (PK: 5.9, EK: 1.3) | 28.7 (28.5 for PK, 30.4 for EK) |
| Griffin et al. ( | 2020 | 2004–2015 | UK | 1,508 | PK, DALK, and epikeratophakia | 66 (72 episodes) | 56.0 ± 20.7 | 49 | 4.77 | 25 months |
| Okonkwo et al. ( | 2018 | 1997–2014 | UK | 759 | PK, DALK, and DSAEK | 41 (59 episodes) | 73.0 ± 19.4 | 53.7 | 5.4 | – |
| Sun et al. ( | 2017 | 2000–2009 | Taiwan | 871 | PK | 52 (67 episodes) | 65.5 ± 16.9 | – | 7.7 | 27.1 ± 28.0 days (range, 0–86 days) |
| Chen et al. ( | 2017 | 2003–2007 | Taiwan | 648 | PK | 42 | 49.1 ± 21.5 | 40.5 | 6.5 | 12.0 ± 9.5 months |
| Edelstein et al. ( | 2016 | 2007–2014 | US | 354,930 | PK, EK, and ALK | 66 | – | – | 0.02 | 29 days (1–216 days range) |
| Constantinou et al. ( | 2013 | 1998–2008 | Australia | 650 | PK | 122 | 75.0 ± 14.8 (failed graft), 61.8 ± 16.3 (clear graft) | 58.8 | 18.8 | 72.0 ± 32.4 (failed graft), 114.0 ± 97.2 (clear graft) |
| Wagoner et al. ( | 2007 | 1998–2002 | US | 2,103 | PK | 102 | 50.4 | 42.2 | 4.9 | 38.2% occurred within 12 months |
| Tavakkoli and Sugar ( | 1994 | 1976–1992 | US | 885 | PK | 36 | – | – | 4.9 | – |
| Leahey et al. ( | 1993 | 1976–1992 | US | 773 | PK | 18 | 58.9 | 72.2 | – | 21.5 months (range 1–53 months) |
| Bates et al. ( | 1990 | 1983–1988 | UK | 1,700 | PK | 30 | 55 | 41 | 1.76 | 10 months (range 1–168) |
| Fong et al. ( | 1988 | 1978–1985 | US | 2,006 | PK | 66 (68 episodes) | 61 | – | 3.3 | – |
| Al-Hazzaa and Tabbara ( | 1988 | 1983–1986 | Saudi Arabia | 947 | PK | 113 | – | 31 | 11.9 | 5.4 months (range 10 days−12 months) |
| Dohse et al. ( | TS (82.6), GF (6.2), corneal scar (5.6) | PK: 44 EK: 45.4 | PK: 21.3 | PK: 10.7 | – | – | GF (67.4), repeat transplantation or keratoprosthesis (33.7), enucleation or evisceration (5.8) | 32.1 | 8.1% (0.0–0.3); 11.6% 0.4–0.6; 30.2% (0.7–1.3); 43.8% (counting fingers or worse) | 47.8 (PK), 38.6 (EK) |
| Griffin et al. ( | TS (89), TG (32), SR (26), HSV (25), atopy/eczema (22), GF (18) | 73 | 23 | 4 | – | – | GF (11), graft rejection episode (3), perforation (13), crystalline keratopathy (6), orbital cellulitis (1), endophthalmitis (1), further PK (24), evisceration (4) | – | ||
| Okonkwo et al. ( | GF (61.4), TG (59.6), SR (19.3) | 30.5 | 18.6 | 8.5 | – | – | Corneal scarring (39), GF (7.3), PED (39), corneal neovascularisation (15), graft rejection (7.3), corneal perforation (4.9) | 60 | ||
| Sun et al. ( | TG, SR, regraft (8.3), corneal scar (7.6), bullous keratopathy (5.8) | 57.9 | 22.4 | 19.7 | – | – | Therapeutic PK, evisceration | 65.7 | – | 37.0 |
| Chen et al. ( | SR (31), lid abnormalities (23.8), PED (23.8), CL (14.3), dry eye (11.9), prior ejection episodes (4.8) | Y | Y | Y | – | – | GF (71.4), hypopyon (21.4), corneal perforation (14.3), wound dehiscence (11.9), endophthalmitis (4.8) | 85 | 33.3% VA >1, 66.7% VA <1 | |
| Edelstein et al. ( | – | 5 | 7 | 81 | 7 | GF, endophthalmitis | – | |||
| Constantinou et al. ( | TS (88.2), TG (50.9), ocular surface disease (19.6), PED (9.8), CL (2.0) | 56.9 | 18.6 | 1.7 | 10.2 | – | GF (51) | 49 | 1.8 ±1.0 in clear-graft group; 1.7 ± 0.9 in failed graft group | |
| Wagoner et al. ( | TS (73.5), SR (71.6), TG (38.2), previous infection (18.6), previous rejection (13.7) | 82.8 | 16.5 | – | – | – | GF (46) | —- | 7.8% (≥0.3); 20.6% (>1.0) | 32.4 |
| Tavakkoli and Sugar ( | PED (64), SR (36) | – | – | – | – | – | 50 | |||
| Leahey et al. ( | TS (72.2) | 94.4 | 22.2 | – | – | – | Scarred corneas (17), GF (16), endophthalmitis | 67 | ||
| Bates et al. ( | TS (96.7), SR (33.3), TG (33.3), GF or recent rejection (23.3), systemic atopy (20), PED (10), CL (3.3) | Y | Y | Y | – | Y | GF (13), corneal perforation (17), endophthalmitis (13), regraft (53) | 23 | ||
| Fong et al. ( | TS (85), SR (50), CL (26), TG (19), previous HSV (15), GF (15), PED (15) | 59 | 38 | 6 | – | – | Descemetocele (6), corneal perforation (12), endophthalmitis (6), enucleation/evisceration (9), wound dehiscence (24), graft failure (16), emergency repeat PK (19), elective repeat PK (13) | – | 10% (no light perception) | |
| Al-Hazzaa and Tabbara ( | Trichiasis (39), PED (38), SR (33), CL (30), dry eye syndrome (27) | Y | Y | 0.1 | 0.3 | – | Endophthalmitis (4) | – | 24% (1.3 or better); 72% (counting fingers to light perception) | >6 months post-operatively |
PK, Penetrating keratoplasty; EK, Endothelial keratoplasty; DALK, Deep anterior lamellar keratoplasty; CL, Contact lens; SR, Suture-related problems; GF, Graft failure; PED, Persistent epithelial defect; HSV, Herpes simplex virus; TS, Topical steroids; TG, Glaucoma drops.